Bacteriophage Laboratory, Ludwik Hirszfeld Institute of Immunology Experimental Therapy, Polish Academy of Sciences, Wrocław, Poland.
Adv Virus Res. 2012;83:73-121. doi: 10.1016/B978-0-12-394438-2.00003-7.
Phage therapy (PT) is a unique method of treatment of bacterial infections using bacteriophages (phages)-viruses that specifically kill bacteria, including their antibiotic-resistant strains. Over the last decade a marked increase in interest in the therapeutic use of phages has been observed, which has resulted from a substantial rise in the prevalence of antibiotic resistance of bacteria, coupled with an inadequate number of new antibiotics. The first, and so far the only, center of PT in the European Union is the Phage Therapy Unit (PTU) established at the Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Wrocław, Poland in 2005. This center continues the rich tradition of PT in Poland, which dates from the early 1920s. The main objective of this chapter is to present a detailed retrospective analysis of the results of PT of 153 patients with a wide range of infections resistant to antibiotic therapy admitted for treatment at the PTU between January 2008 and December 2010. Analysis includes the evaluation of both the efficacy and the safety of PT. In general, data suggest that PT can provide good clinical results in a significant cohort of patients with otherwise untreatable chronic bacterial infections and is essentially well tolerated. In addition, the whole complex procedure employed to obtain and characterize therapeutic phage preparations, as well as ethical aspects of PT, is discussed.
噬菌体疗法 (PT) 是一种使用噬菌体(phages)——专门杀死细菌的病毒——治疗细菌感染的独特方法,包括其抗生素耐药株。在过去的十年中,人们对噬菌体治疗的兴趣显著增加,这是由于细菌对抗生素的耐药性显著增加,而新抗生素的数量却不足。欧盟第一个也是迄今为止唯一一个噬菌体治疗中心是 2005 年在波兰弗罗茨瓦夫 Ludwik Hirszfeld 免疫与实验治疗研究所建立的噬菌体治疗单位 (PTU)。该中心延续了波兰噬菌体治疗的悠久传统,可追溯到 20 世纪 20 年代初。本章的主要目的是详细回顾性分析 2008 年 1 月至 2010 年 12 月期间在 PTU 接受治疗的 153 名患有广泛抗生素耐药感染的患者的噬菌体治疗结果。分析包括对噬菌体治疗的疗效和安全性进行评估。总的来说,数据表明,噬菌体治疗可以为大量其他治疗方法无效的慢性细菌感染患者提供良好的临床效果,并且基本上可以耐受。此外,还讨论了获得和表征治疗性噬菌体制剂的整个复杂过程以及噬菌体治疗的伦理方面。